Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Share-based Compensation: 2012-2024

Historic Share-based Compensation for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to $21.4 million.

  • Theravance Biopharma's Share-based Compensation fell 7.80% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.8 million, marking a year-over-year decrease of 7.34%. This contributed to the annual value of $21.4 million for FY2024, which is 15.68% down from last year.
  • Theravance Biopharma's Share-based Compensation amounted to $21.4 million in FY2024, which was down 15.68% from $25.4 million recorded in FY2023.
  • Over the past 5 years, Theravance Biopharma's Share-based Compensation peaked at $63.0 million during FY2020, and registered a low of $21.4 million during FY2024.
  • Its 3-year average for Share-based Compensation is $28.8 million, with a median of $25.4 million in 2023.
  • Its Share-based Compensation has fluctuated over the past 5 years, first climbed by 4.18% in 2020, then slumped by 36.15% in 2023.
  • Over the past 5 years, Theravance Biopharma's Share-based Compensation (Yearly) stood at $63.0 million in 2020, then declined by 1.45% to $62.1 million in 2021, then crashed by 35.98% to $39.7 million in 2022, then crashed by 36.15% to $25.4 million in 2023, then declined by 15.68% to $21.4 million in 2024.